TLDR
- Nuvation Bio (NUVB) stock reached a new 52-week high of $5.57, up 85% over the past year and 109% in six months.
- B.Riley initiated coverage with a Buy rating and $12 price target, representing 150% upside potential.
- Lead drug IBTROZI recorded 204 new patient starts in Q3 2025, exceeding investor expectations in its first quarter on the market.
- Q3 revenue hit $13.1 million, crushing forecasts of $6.8 million with a 93% earnings surprise.
- Citizens raised price target from $6 to $8, while B.Riley set target at $12 based on strong commercial launch.
Nuvation Bio stock climbed to $5.57 on Tuesday, marking its highest level in a year. The biotech company has delivered an 85% return over the past 12 months.
The rally gained momentum in recent months, with shares jumping 109% over the past six months. Trading volume has picked up as institutional interest grows.
B.Riley initiated coverage of NUVB with a Buy rating on Wednesday. Analyst Mayank Mamtani set a $12 price target, implying 150% upside from the current $4.80 level.
The optimistic outlook centers on IBTROZI’s commercial performance. The drug received FDA approval in June 2025 for treating ROS1-positive non-small cell lung cancer.
IBTROZI logged 204 new patient starts in the third quarter. This figure beat analyst expectations for the drug’s debut quarter on the market.
The company reported Q3 revenue of $13.1 million. This topped forecasts of $6.8 million by 93%, marking a strong earnings surprise.
Commercial Traction Drives Momentum
B.Riley highlighted IBTROZI’s clinical profile as a next-generation ROS1 tyrosine kinase inhibitor. The drug demonstrated high response rates in Phase 3 TRUST-I and II trials involving roughly 300 patients.
Brain penetration sets IBTROZI apart from competitors. This feature addresses a critical need in lung cancer treatment where brain metastases are common.
The analyst firm compared IBTROZI’s potential to other successful lung cancer drugs. AstraZeneca’s Tagrisso and Pfizer’s Lorbrena both generated multi-billion dollar markets in their respective mutation-defined segments.
Nuvation Bio maintains a market cap of $1.81 billion. The company holds strong liquidity with a current ratio of 8.48 and more cash than debt.
Analyst Support Builds
Citizens previously raised its price target to $8 from $6. The firm maintained its Market Outperform rating following the Q3 results.
B.Riley sees the most value in frontline use of IBTROZI. The drug showed effectiveness in both treatment-naive and previously treated patients.
The launch trajectory is reportedly outpacing similar ROS1 inhibitor introductions. This performance strengthens the case for continued market share gains.
NUVB trades with a beta of 1.64, indicating higher volatility than the broader market. Investors should expect larger price swings in both directions.
The company posted earnings per share of -$0.16 in Q3. This came in slightly better than the expected -$0.17 loss.
Revenue growth in the last twelve months reached 1,137%. This metric reflects the transition from clinical-stage to commercial operations.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
